Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

11 trials with published results (42%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 26 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

27%

7 trials in Phase 3/4

Results Transparency

42%

11 of 26 completed with results

Key Signals

11 with results100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (1)
P 2 (17)
P 3 (7)

Trial Status

Completed26

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT03923634Not ApplicableCompletedPrimary

Princess® RICH for the Correction of Fine Lines

NCT04157686Phase 3Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT03785145Phase 3CompletedPrimary

MT10109L in the Treatment of Lateral Canthal Lines

NCT03732833Phase 3CompletedPrimary

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

NCT03911102Phase 2CompletedPrimary

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT04249687Phase 3CompletedPrimary

Treatment of Moderate to Severe Lateral Canthal Lines

NCT04225260Phase 3Completed

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT03721016Phase 3Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

NCT03839693Phase 2CompletedPrimary

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

NCT03326856Phase 2CompletedPrimary

ET-01 in Subjects With Lateral Canthal Lines

NCT03655691Phase 2CompletedPrimary

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT04143854Phase 2CompletedPrimary

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines

NCT01064518Phase 2CompletedPrimary

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT00884234Phase 2CompletedPrimary

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00247559Phase 2CompletedPrimary

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

NCT02248844CompletedPrimary

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

NCT02195687Phase 3CompletedPrimary

BOTOX® in the Treatment of Crow's Feet Lines in China

NCT01951742Phase 2CompletedPrimary

Dose Finding Study In Subjects With Crow's Feet

NCT01124552Phase 2CompletedPrimary

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT00907387Phase 2CompletedPrimary

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Scroll to load more

Research Network

Activity Timeline